NSRX

Nasus Pharma Ltd.

$2.98

1.70%
SectorHealthcareIndustryDrug Manufacturers - GeneralCountryIsrael

Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.

Source: Yahoo Finance
AI summary

Price & performance

1M-18.4%
3M+5.6%
YTD-57.6%
1Y-58.9%
52-week range—
Beta0.65
Full chart and returns against a benchmark

Q-Score

40/ 100

Quality against peers; 50 is the peer median.

Growth—
Risk41
Performance30
Valuation55
Profitability36
Leverage81
Sentiment59
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$1.2B
Net income-$5.9M
Net margin-0.5%
Historical fundamentals

Red flags in filings

2active red flags
Going-concern doubtMar 25, 2026
Material weakness in controlsMar 25, 2026
Filings, findings and the timeline

Revenue exposure

Regions, segments, customers and suppliers

Valuation

NSRXIndustryP/E—38.98P/S0.036.74EV/EBITDA—40.57P/B12.6310.26PEG——
Dividend yield0.00%
Every valuation metric